Trial Profile
Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus insulin treatment (BBIT) regimen to a basal supported oral therapy (BOT) in patients with Type 2 Diabetes – a randomised double-blinded study – a randomised double-blinded study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DapaSaxaBBIT
- 07 Feb 2020 Status changed from recruiting to completed.
- 07 Feb 2020 Status changed from completed to discontinued.
- 17 May 2018 Planned End Date changed from 1 Feb 2018 to 1 Jun 2020.